Maternal immune activation leads to age-related behavioral and immunological changes in male rat offspring - The effect of antipsychotic drugs

Pharmacological Reports

Volumn 64, Issue 6, 2012, Pages 1400-1410

  Basta Kaim, Agnieszka ^a   Szczȩeny, Ewa ^a   Leśkiewicz, Monika ^a   Głombik, Katarzyna ^a   Ślusarczyk, Joanna ^a   Budziszewska, Bogusława ^a   Regulska, Magdalena ^a   Kubera, Marta ^a   Nowak, Wojciech ^b   Wȩdzony, Krzysztof ^a   Lasoń, Władyłsaw ^a  

^a INSTITUTE OF PHARMACOLOGY   (Poland)

^b JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

Chlorpromazine; Clozapine; Cytokines; Proliferative activity of splenocytes; Schizophrenia

Indexed keywords

CHLORPROMAZINE; CLOZAPINE; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; MITOGEN ACTIVATED PROTEIN KINASE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; B LYMPHOCYTE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG ACTIVITY; DRUG EFFICACY; DRUG SAFETY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; IMMUNOLOGY; LYMPHOCYTE PROLIFERATION; MALE; NERVE CELL DIFFERENTIATION; NONHUMAN; PREPULSE INHIBITION; PROTEIN BLOOD LEVEL; RAT; SCHIZOPHRENIA; SENSORY GATING; SPLEEN CELL; T LYMPHOCYTE;

EID: 84873743992     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/S1734-1140(12)70937-4     Document Type: Article

References (52)

1. Akiyama K: Serum levels of soluble IL-2 receptor alpha, IL-6 and IL-1 receptor antagonist in schizophrenia before and during neuroleptic administration. Schizophr Res, 1999, 37, 97-106.
2. Baker GA, Santalo R, Blumenstein J: Effects of psychotropic agents upon the blastogenic response of human T-lymphocytes. Biol Psychiatry, 1997, 12, 159-169.
3. Baker I, Masserano J, Wyatt RJ: Serum cytokine concentrations in patients with schizophrenia. Schizophr Res, 1996, 20, 199-203. (Pubitemid 26387520)
4. Basta-Kaim A, Budziszewska B, Jagła G, Nowak W, Kubera M, Lasoń W: Inhibitory effect of antipsychotic drugs on the Con A- and LPS-induced proliferative activity of mouse splenocytes: a possible mechanism of action. J Physiol Pharmacol, 2006, 57, 247-264. (Pubitemid 44077749)
5. Basta-Kaim A, Budziszewska B, Leśkiewicz M, Fijał K, Regulska M, Kubera M, Wȩdzony K, Lasoń W: Hyperactivity of the hypothalamus-pituitary-adrenal axis in lipopolysaccharide-induced neurodevelopmental model of schizophrenia in rats: effects of antipsychotic drugs. Eur J Pharmacol, 2011, 650, 586-595.
6. Basta-Kaim A, Fijał K, Budziszewska B, Regulska M, Leśkiewicz M, Kubera M, Gołembiowska K et al.: Prenatal lipopolysaccharide treatment enhances MK-801- induced psychotomimetic effects in rats. Pharmacol Biochem Behav, 2011, 98, 241-249.
7. Basta-Kaim A, Kubera M, Budziszewska B, Siwanowicz J, Lasoń W: Effect of some antipsychotic drugs on immunoreactivity in C57BL/6 mice. Pol J Pharmacol, 2002, 54, 737-742. (Pubitemid 36124530)
8. Bilbo SD, Schwarz JM: Early-life programming of later-life brain and behavior: a critical role for the immune system. Front Behav Neurosci, 2009, 3, 14.
9. Boksa P: Effects of prenatal infection on brain development and behavior: a review of findings from animal models. Brain Behav Immun, 2010, 24, 881-897.
10. Borovcanin M, Jovanovic I, Radosavljevic G, Djukic Dejanovic S, Bankovic D, Arsenijevic N, Lukic ML: Elevated serum level of type-2 cytokine and low IL-17 in first episode psychosis and schizophrenia in relapse. J Psychiatr Res, 2012, 46, 1421-1426.
11. Borrell J, Vela JM, Arévalo-Martin A, Molina-Holgado E, Guaza C: Prenatal immune challenge disrupts sensori-motor gating in adult rats. Implications for the etiopathogenesis of schizophrenia. Neuropsychopharmacology, 2002, 26, 204-215. (Pubitemid 34093083)
12. Brown AS, Derkits EJ: Prenatal infection and schizophrenia: a review of epidemiologic and translational studies. Am J Psychiatry, 2010, 167, 261-280.
13. Cai Z, Pan ZL, Pang Y, Evans OB, Rhodes PG: Cytokine induction in fetal rat brains and brain injury in neonatal rats after maternal lipopolysaccharide administration. Pediatr Res, 2000, 47, 64-72. (Pubitemid 30038893)
14. Chen ML, Tsai TC, Lin YY, Tsai YM, Wang LK, Lee MC, Tsai FM: Antipsychotic drugs suppress the AKT/NF-κB pathway and regulate the differentiation of T-cell subsets. Immunol Lett, 2011, 140, 81-91.
15. Chen ML, Tsai TC, Wang LK, Lin YY, Tsai YM, Lee MC, Tsai FM: Clozapine inhibits Th1 cell differentiation and causes the suppression of IFN-γ production in peripheral blood mononuclear cells. Immunopharmacol Immunotoxicol, 2012, 34, 686-694.
16. Davison K: Autoimmunity in psychiatry. Br J Psychiatry, 2012, 200, 353-355.
17. Deverman BE, Patterson PH: Cytokines and CNS development. Neuron, 2009, 64, 61-78.
18. Dirks A, Groenink L, Westphal KG, Olivier JD, Verdouw PM, van der Gugten J, Geyer MA, Olivier B: Reversal of startle gating deficits in transgenic mice overexpressing corticotropin-releasing factor by antipsychotic drugs. Neuropsychopharmacology, 2003, 28, 1790-1798. (Pubitemid 41070844)
19. Drzyzga L, Obuchowicz E, Marcinowska A, Herman ZS: Cytokines in schizophrenia and the effects of antipsychotic drugs. Brain Behav Immun, 2006, 20, 532-545. (Pubitemid 44528954)
20. Gilmore JH, Fredrik Jarskog L, Vadlamudi S, Lauder JM: Prenatal infection and risk for schizophrenia: IL-1β, IL-6, and TNF-α inhibit cortical neuron dendrite development. Neuropsychopharmacology, 2004, 29, 1221-1229. (Pubitemid 38780645)
21. Himmerich H, Schönherr J, Fulda S, Sheldrick AJ, Bauer K, Sack U: Impact of antipsychotics on cytokine production in-vitro. J Psychiatr Res, 2011, 45, 1358-1365.
22. Hinze-Selch D, Becker EW, Stein GM, Berg PA, Mullington J, Holsboer F, Pollmächer T: Effects of clozapine on in vitro immune parameters: a longitudinal study in clozapine-treated schizophrenic patients. Neuropsychopharmacology, 1998, 19, 114-122. (Pubitemid 28288437)
23. Krause DL, Wagner JK, Wildenauer A, Matz J, Weidinger E, Riedel M, Obermeier M et al.: Intracellular monocytic cytokine levels in schizophrenia show an alteration of IL-6. Eur Arch Psychiatry Clin Neurosci, 2012, 262, 393-401.
24. Maino K, Gruber R, Riedel M, Seitz N, Schwarz M, Müller N: T- and B-lymphocytes in patients with schizophrenia in acute psychotic episode and the course of the treatment. Psychiatry Res, 2007, 152, 173-180. (Pubitemid 47212477)
25. Martínez-Gras I, García-Sánchez F, Guaza C, Rodríguez-Jiménez R, Andrés-Esteban E, Palomo T, Rubio G, Borrell J: Altered immune function in unaffected first-degree biological relatives of schizophrenia patients. Psychiatry Res, 2012, 200, 1022-1025.
26. Monteleone P, Fabrazzo M, Tortorella A, Maj M: Plasma levels of interleukin-6 and tumor necrosis factor alpha in chronic schizophrenia: effects of clozapine treatment. Psychiatry Res, 1997, 71, 11-17. (Pubitemid 27304310)
27. Moore KW, de Waal Malefyt R, Coffman RL, O'Garra A: Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol, 2001, 19, 683-765. (Pubitemid 32368050)
28. Müller N, Wagner JK, Krause D, Weidinger E, Wildenauer A, Obermeier M, Dehning S et al.: Impaired monocyte activation in schizophrenia. Psychiatry Res, 2012, 198, 341-346.
29. Na KS, Kim YK: Monocytic, Th1 and Th2 cytokine alterations in the pathophysiology of schizophrenia. Neuropsychobiology, 2007,56, 55-63.
30. Pollmächer T, Haack M, Schuld A, Kraus T, Hinze-Selch D: Effects of antipsychotic drugs on cytokine networks. J Psychiatr Res, 2000, 34, 369-382. (Pubitemid 32101554)
31. Rao VS, Carvalho AC, Trevisan MT, Andrade GM, Nobre-Júnior HV, Moraes MO, Magãlhes HI, Morais TC, Santos FA: Mangiferin ameliorates 6-hydroxy-dopamine- induced cytotoxicity and oxidative stress in ketamine model of schizophrenia. Pharmacol Rep, 2012, 64, 848-856.
32. RinconM, Flavell RA, Davis RA: The JNK and p38 MAPK kinase signaling pathways in T cell-mediated immune responses. Free Radic BiolMed, 2000, 28, 1328-1337. (Pubitemid 30621477)
33. Røge R, Møller BK, Andersen CR, Correll CU, Nielsen J. Immunomodulatory effects of clozapine and their clinical implications: what have we learned so far? Schizophr Res, 2012, 140, 204-213.
34. Romero E, Ali C, Molina-Holgado E, Castellano B, Guaza C, Borrell J. Neurobehavioral and immunological consequences of prenatal immune activation in rats. Influence of antipsychotics. Neuropsychopharmacology, 2007, 32, 1791-1804. (Pubitemid 47076375)
35. Romero E, Guaza C, Castellano B, Borrell J. Ontogeny of sensorimotor gating and immune impairment induced by prenatal immune challenge in rats: implications for the etiopathology of schizophrenia. Mol Psychiatry, 2010, 15, 372-383.
36. Rothermundt M, Arolt V, Bayer TA: Review of immunological and immunopathological findings in schizophrenia. Brain Behav Immun, 2001, 15, 319-339. (Pubitemid 34044519)
37. Schleuning MJ, Duggan A, Reem GH: Inhibition by chlorpromazine of lymphokine-specific mRNA expression in human thymocytes. Eur J Immunol, 1989, 19, 1491-1495.
38. Schwarz MJ, Müller N, Riedel M, Ackenheil M: The Th2-hypothesis of schizophrenia: a strategy to identify a subgroup of schizophrenia caused by immune mechanisms. Med Hypotheses, 2001, 56, 483-486. (Pubitemid 32397883)
39. Sidhom O, Laadhar L, Zitouni M, Ben Alaya N, Rafrafi R, Kallel-Sellami M, Lahmar H et al.: Spectrum of auto-antibodies in Tunisian psychiatric inpatients. Immunol Invest, 2012, 41, 538-549.
40. Silberman DM, Zorrilla-Zubilete M, Cremaschi GA, Genaro AM: Protein kinase C-dependent NF-κB activation is altered in T cells by chronic stress. Cell Mol Life Sci, 2005, 62, 1744-1754. (Pubitemid 41176055)
41. Smith RS, Maes M: The macrophage-T-lymphocyte theory of schizophrenia: additional evidence. Med Hypotheses, 1995, 45, 135-141.
42. Song C, Lin A, Kenis G, Bosmans E, Maes M: Immuno-suppressive effects of clozapine and haloperidol: enhanced production of the interleukin-1 receptor antagonist. Schizophr Res, 2000, 42, 157-164. (Pubitemid 30163081)
43. Spulber S, Schultzberg M. Connection between inflammatory processes and transmittor function - Modulatory effects of interleukin-1. Prog Neurobiol, 2010, 90, 256-262.
44. Strous R, Shoenfeld Y. Schizophrenia, autoimmunity and immune system dysregulation: a comprehensive model updated and revisited. J Autoimmun, 2006, 27, 71-80. (Pubitemid 44528264)
45. Szuster-Ciesielska A, Słotwińska M, Stachura A, Marmurowska-Michałowska H, Kandefer-Szerszeń M: Neuroleptics modulate cytokine and reactive oxygen species production in blood leukocytes of healthy volunteers. Arch Immunol Ther Exp (Warsz), 2004, 52, 59-67. (Pubitemid 39317972)
46. Tohmi M, Tsuda N, Watanabe Y, Kakita A, Nawa H: Perinatal inflammatory cytokine challenge results in distinct neurobehavioral alterations in rats: implication in psychiatric disorders of developmental origin. Neurosci Res, 2004, 50, 67-75. (Pubitemid 39024303)
47. Toomla O, Toomaspoeg L: Immunoglobulin concentrations in schizophrenic patiens in relation to psychopathology. Nord J Psychiatry, 1996, 50, 49-53. (Pubitemid 26063141)
48. Urakubo A, Jarskog LF, Lieberman JA, Gilmore JH: Prenatal exposure to maternal infection alters cytokine expression in the placenta, amniotic fluid, and fetal brain. Schizophr Res, 2001, 47, 27-36. (Pubitemid 32121768)
49. Vicari AP, Trinchieri G: Interleukin-10 in viral diseases and cancer: exiting the labyrinth? Immunol Rev, 2004, 202, 223-236. (Pubitemid 39576915)
50. Wȩdzony K, Fijał K, Maćkowiak M, Chocyk A, Zaja̧czkowski W: Impact of postnatal blockade of N-methyl- D-aspartate receptors on rat behavior: a search for a new developmental model of schizophrenia. Neuroscience, 2008, 60, 856-864.
51. Wȩdzony K, Maćkowiak M, Zaja̧czkowski W, Fijał K, Chocyk A, Czyrak A: WAY 100135, an antagonist of 5-HT1A serotonin receptors, attenuates psychotomimetic effects of MK-801. Neuropsychopharmacology, 2000, 23, 547-559.
52. Zuckerman L, Weiner I: Maternal immune activation leads to behavioral and pharmacological changes in the adult offspring. J Psychiatr Res, 2005, 39, 311-323. (Pubitemid 40255916)